Royalty Pharma Plc (RPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Royalty Pharma Plc (RPRX) has a cash flow conversion efficiency ratio of 0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($827.15 Million) by net assets ($9.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Royalty Pharma Plc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Royalty Pharma Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Royalty Pharma Plc for a breakdown of total debt and financial obligations.
Royalty Pharma Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Royalty Pharma Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grasim Industries Limited
NSE:GRASIM
|
-0.049x |
|
Naver Corporation
KO:035420
|
0.036x |
|
VONOVIA SE ADR 1/2/O.N
F:VNAA
|
N/A |
|
POP MART INT.GRP.DL-0001
F:735
|
N/A |
|
Reddit, Inc.
NYSE:RDDT
|
0.091x |
|
Williams-Sonoma Inc
NYSE:WSM
|
0.154x |
|
Smurfit WestRock plc
NYSE:SW
|
0.061x |
|
Tenaga Nasional Bhd
KLSE:5347
|
0.068x |
Annual Cash Flow Conversion Efficiency for Royalty Pharma Plc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Royalty Pharma Plc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see RPRX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.71 Billion | $2.49 Billion | 0.256x | -4.27% |
| 2024-12-31 | $10.34 Billion | $2.77 Billion | 0.268x | -9.64% |
| 2023-12-31 | $10.08 Billion | $2.99 Billion | 0.296x | +31.63% |
| 2022-12-31 | $9.53 Billion | $2.14 Billion | 0.225x | +14.34% |
| 2021-12-31 | $10.25 Billion | $2.02 Billion | 0.197x | +44.87% |
| 2020-12-31 | $14.97 Billion | $2.03 Billion | 0.136x | -49.94% |
| 2019-12-31 | $6.14 Billion | $1.67 Billion | 0.271x | -23.64% |
| 2018-12-31 | $4.55 Billion | $1.62 Billion | 0.356x | +12.03% |
| 2017-12-31 | $4.47 Billion | $1.42 Billion | 0.317x | +9183.95% |
| 2016-12-31 | $4.46 Billion | $-15.58 Million | -0.003x | +35.22% |
| 2015-12-31 | $4.70 Billion | $-25.33 Million | -0.005x | +99.19% |
| 2014-12-31 | $44.02 Million | $-29.33 Million | -0.666x | -240.37% |
| 2003-12-31 | $23.49 Million | $11.15 Million | 0.475x | +50.95% |
| 2002-12-31 | $26.85 Million | $8.45 Million | 0.315x | -- |
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more